Pyrotinib 320mg

DRUG2 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanghai Jiao Tong University School of Medicine

Conditions

HER2 + Breast CancerMetastatic Breast Cancer With HER2 Positive

Phase 2

SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer

Not yet recruitingNCT07132242

Cancer Institute and Hospital, Chinese Academy of Medical SciencesMetastatic Breast Cancer With HER2 Positive

Start: 2025-08-30End: 2028-12-31Target: 84Updated: 2025-08-20

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

RecruitingNCT07393425

Shanghai Jiao Tong University School of MedicineHER2 + Breast Cancer

Start: 2026-02-02End: 2032-09-30Target: 50Updated: 2026-02-06